Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 14/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924236 | 0.93 | KDM1A (0.35) | HDAC7HCRTR1HCRTR2CYP46A1 | |
| SCHEMBL2924875 | 0.93 | HCRTR2 (0.37) | HDAC7HCRTR1HCRTR2CYP46A1CHRM3 | |
| SCHEMBL2928731 | 0.91 | CYP46A1 (0.42) | HDAC7HCRTR1HCRTR2CYP46A1 | |
| SCHEMBL2931971 | 0.90 | HCRTR1 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL2930272 | 0.89 | CHRM1 (0.46) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL2929505 | 0.89 | HCRTR2 (0.43) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL2925064 | 0.89 | HCRTR2 (0.43) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL2925883 | 0.87 | CHRM1 (0.33) | HDAC7HCRTR1HCRTR2CYP46A1 | |
| SCHEMBL2931139 | 0.87 | HCRTR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL3417003 | 0.87 | HCRTR1 (0.45) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | claimed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | claimed |
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HDAC7 579/4885HCRTR1 1/4885HCRTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.